Beijing Jingguoguan Yizhuang Kangqiao Industrial Investment Fund Completes Strategic Acquisition of Eisai's Pariet® China Business

Investment Circle (ID: pedaily2012) April 16 News: On April 15, Beijing Jingguan Yizhuang Kangqiao Industrial Investment Fund (referred to as "M&A Fund") announced that it had completed the acquisition of Eisai Co., Ltd.'s proton pump inhibitor (PPI) Pari-et.^®( Generic Name: Rabeprazole Sodium ) Strategic Acquisition in China.

This acquisition is the first investment of the first RMB healthcare M&A fund established by CBC Group in cooperation with Beijing State-owned Capital Operation and Management Co., Ltd. ("BSOCOM") and the biopharmaceutical platform company under Yizhuang Holdings.

Pariet^®Pariet is a globally renowned proton pump inhibitor (PPI) discovered and developed by Eisai. It has been approved in more than 100 countries and regions for the treatment of gastrointestinal diseases such as gastric ulcers, duodenal ulcers, and reflux esophagitis. The product has been marketed in China since 2000. This acquisition aligns closely with CBC Group's vision of building a leading gastrointestinal treatment platform in China. As the demand for high-quality treatment solutions in China continues to grow, CBC Group will further promote Pariet.^®Incorporating its mature pharmaceutical portfolio, and relying on its unique "investor-operator" model, it is committed to improving operational efficiency, driving innovation, and achieving scaled development, thereby enhancing patients' access to trusted therapies and benefiting a wide range of patients in China and surrounding regions.

CEO of CBC Group, Fu WeiSaid that, this acquisition is an important strategic step for CBC Group to provide transformative healthcare solutions in Asia. The gastrointestinal treatment market has enormous potential with a large number of unmet patient needs, and Pariet^®As a key asset, it is highly aligned with our expertise and long-term vision. With our deep experience and practical approaches accumulated in the healthcare industry, we are committed to improving the accessibility of essential treatments for patients and healthcare providers while continuously creating social value.

Ren Peng, Chairman and General Manager of Shunxi FundSaid that, this time for Pariet^®The acquisition of the China business is another successful practice by CBC Group and Shunxi Fund in promoting the upgrading of the healthcare industry. We look forward to bringing more high-quality medical resources to Chinese patients through the synergistic effects of the fund, while supporting Beijing in building itself into a globally leading healthcare industry hub.

Feng Yanhui, Senior Vice President of Eisai Global and President of Eisai ChinaWe believe that CBC Group is the right partner to further expand Pariet^®The ideal partner with influence in the Chinese market, capable of ensuring that patients continue to benefit from this trusted therapy. This asset divestiture will enable Eisai to focus its resources on other medium- and long-term business growth areas, thereby better meeting the diverse needs of patients and their families, and bringing them greater well-being.

Beijing Summit Biomedical Co., Ltd. ("Summit Bio") as a subsidiary controlled by the M&A fund, will be responsible for managing Pari-et.^®In China's operations. During the transition period, Eisai will oversee the transfer of production and marketing authorization to ensure a smooth handover of the business. In the future, Summit Biologics will continue to optimize market access and explore more innovative opportunities in the gastrointestinal care field.

This article is sourced from Pedaily, original text: https://news.pedaily.cn/202504/548409.shtml